Results from the TITAN-RCC trial add support for the use of ipilimumab alongside nivolumab in patients with intermediate- or high-risk advanced renal cell carcinoma, showing that a personalized strategy is feasible for nonresponders.
Blood-based next-generation sequencing can be used to identify patients with non-small-cell lung cancer and ALK fusions who will benefit from treatment with alectinib, show results of the phase II/III blood-first assay screening trial.
An interim analysis of the IMpower110 study has demonstrated an overall survival improvement with atezolizumab versus chemotherapy in treatment-naïve patients with stage IV non-small-cell lung cancer and high levels of PD-L1 expression.
Treatment with the PARP inhibitor olaparib improves the outcomes of men with metastatic castration-resistant prostate cancer harboring deleterious mutations in homologous recombination repair genes, show trial results.
Individuals with advanced non-small-cell lung cancer derive an overall survival benefit from first-line treatment with nivolumab plus ipilimumab irrespective of PD-L1 expression, report the CheckMate 227 investigators.
Initial results from the phase II TROPHY-U-01 trial confirm the antitumor activity of sacituzumab govitecan in patients with metastatic urothelial carcinoma that has progressed after platinum chemotherapy or checkpoint inhibition.
Pembrolizumab does not confer a progression free survival or overall survival advantage in previously treated patients with advanced malignant pleural mesothelioma, suggest findings from the PROMISE-meso trial.
Adding apalutamide to androgen deprivation therapy does not result in increased levels of pain or fatigue, relative to placebo, nor does it negatively impact overall health-related quality of life, shows an analysis of data from the TITAN study.
Findings from the JAVELIN Renal 101 trial of patients with advanced renal cell carcinoma suggest front-line use of avelumab plus axitinib is superior to sunitinib for patients with sarcomatoid histology and for those who did not undergo upfront cytoreductive nephrectomy.
Ultra-hypofractionated stereotactic body radiotherapy does not increase the risk for acute toxicity over standard of care radiotherapy in men with localized prostate cancer, according to a phase III trial.
Adding atezolizumab to chemotherapy significantly prolongs progression-free survival in the first-line advanced urothelial cancer setting, according to the IMvigor130 trial results presented at the ESMO Congress 2019.
Research published in JAMA Oncology shows that patients with EGFR-mutated lung adenocarcinoma have prolonged progression free survival when tyrosine kinase inhibitor treatment is supplemented with metformin.
The combination of durvalumab plus chemotherapy is associated with better patient-reported outcomes than chemotherapy alone, suggests data from the CASPIAN trial comprising treatment-naïve individuals with extensive-stage small-cell lung cancer.
Cabazitaxel could be an option for men with metastatic castration-resistant prostate cancer who have progressed after treatment with docetaxel and an androgen signaling-targeted agent, suggest trial findings.
The FLAURA trial comparing osimertinib with erlotinib or gefitinib in the first-line treatment of EGFR-mutated, advanced non-small-cell lung cancer has shown positive overall survival results favoring the third-generation EGFR–tyrosine kinase inhibitor.
An interim analysis from the SPARTAN trial points to an overall survival benefit with the use of apalutamide alongside androgen deprivation therapy for nonmetastatic castration-resistant prostate cancer.
Men with metastatic hormone-naïve prostate cancer have improved outcomes with the addition of docetaxel to androgen deprivation therapy irrespective of whether they have high or low burden of disease, indicates an analysis of the STAMPEDE trial.